EGF and cancer: Researchers have used inverse docking technology to screen potential cancer treatment drugs and discovered that only dioscin had the following properties for cancer treatment: it may be a TOP1 inhibitor, which halts the cancer cell cycle and DNA replication; it down-regulates epidermal growth factor receptor (EGFR) and EGF to inhibit growth of a vascular supply; it also has antiinflammatory activity by regulating the JNK signaling pathway to suppress cancer (Yin et al., 2015).